Skip to main content
. 2023 Jan 14;2023:9966355. doi: 10.1155/2023/9966355

Figure 2.

Figure 2

TBM attenuated inflammation in response to DOX treatment in vitro. (a–c) The relative mRNA levels of Il-6, Il-1β, and Tnf in DOX treated H9c2 cells (n = 5). (d–h) Western blotting assays of IL-6, IL-1β, and TNF-α in each group (n = 3). (i–k) Levels of IL-6, IL-1β, and TNF-α in cell supernatant determined by ELISA (n = 4). Values indicate the mean ± SD. ∗P < 0.05 versus the CON group and the TBM group; #P < 0.05 versus the DOX group; ns (not significant) versus the CON group.